Denmark - Dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

medipha sante sn - letrozol - filmovertrukne tabletter - 2,5 mg

Denmark - Dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

orifarm a/s - ethinylestradiol, etonogestrel - vaginalindlæg - 120+15 mikg/24 timer

Denmark - Dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

paranova danmark a/s - ethinylestradiol, etonogestrel - vaginalindlæg - 120+15 mikg/24 timer

Denmark - Dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

bayer ab - drospirenon, ethinylestradiol - filmovertrukne tabletter - 3,0 mg+0,020 mg

Denmark - Dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

bayer ab - drospirenon, ethinylestradiol - filmovertrukne tabletter - 3,0 mg + 0,020 mg

Uni Eropa - Dansk - EMA (European Medicines Agency)

ultragenyx germany gmbh - vestronidase alfa - mucopolysaccharidosis vii - enzymer - mepsevii er indiceret til behandling af ikke-neurologiske manifestationer af mucopolysaccharidosis vii (mps vii; sly syndrom).

Uni Eropa - Dansk - EMA (European Medicines Agency)

regeneron ireland designated activity company (dac) - cemiplimab - carcinom, squamous cell - antineoplastiske midler - cutaneous squamous cell carcinomalibtayo as monotherapy is indicated for the treatment of adult patients with metastatic or locally advanced cutaneous squamous cell carcinoma (mcscc or lacscc) who are not candidates for curative surgery or curative radiation. basal cell carcinomalibtayo as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic basal cell carcinoma (labcc or mbcc) who have progressed on or are intolerant to a hedgehog pathway inhibitor (hhi). non-small cell lung cancerlibtayo as monotherapy is indicated for the first-line treatment of adult patients with non-small cell lung cancer (nsclc) expressing pd-l1 (in ≥ 50% tumour cells), with no egfr, alk or ros1 aberrations, who have:locally advanced nsclc who are not candidates for definitive chemoradiation, ormetastatic nsclc. libtayo in combination with platinum‐based chemotherapy is indicated for the first‐line treatment of adult patients with nsclc expressing pd-l1 (in ≥ 1% of tumour cells), with no egfr, alk or ros1 aberrations, who have:locally advanced nsclc who are not candidates for definitive chemoradiation, ormetastatic nsclc. cervical cancerlibtayo as monotherapy is indicated for the treatment of adult patients with recurrent or metastatic cervical cancer and disease progression on or after platinum-based chemotherapy.

Denmark - Dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

2care4 aps - ethinylestradiol, etonogestrel - vaginalindlæg - 120+15 mikg/24 timer

Denmark - Dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

abacus medicine a/s - letrozol - filmovertrukne tabletter - 2,5 mg

Uni Eropa - Dansk - EMA (European Medicines Agency)

sandoz pharmaceuticals d.d. - nelarabin - forløber t-celle lymfoblastisk leukæmi-lymfom - antineoplastiske midler - nelarabine er indiceret til behandling af patienter med t-celle akut lymfoblastær leukæmi (t-all) og t-celle lymphoblastic lymphoma (t-lbl), hvis sygdommen ikke har reageret eller har fået tilbagefald efter behandling med mindst to kemoterapi regimer. due to the small patient populations in these disease settings, the information to support these indications is based on limited data.